Dexcom (Nasdaq:DXCM) as we speak unveiled its technique to broaden entry to its glucose-sensing know-how for hundreds of thousands around the globe.
San Diego-based Dexcom held an Investor Day occasion through which it revealed plans to deliver a brand new product to market within the U.S. in 2024. The corporate designed its new product for individuals who don’t use insulin — roughly 70% of Individuals with diabetes.
Dexcom mentioned it plans for its new product to characteristic a 15-day sensor and a cash-pay choice. The corporate needs to supply a brand new software program expertise tailor-made for these not on insulin.
Earlier this yr, Dexcom Chair, President and CEO, Kevin Sayer, hinted at potential new avenues when speaking to Drug Delivery Business News. He defined that the corporate needed to broaden its focus, even revising its mission assertion. Dexcom up to date its mission — enabling individuals to take management of diabetes — by altering “diabetes” to “well being.”